Brain Cancer | Topics

Clinical Benefit Observed With Dabrafenib Plus Trametinib Combo for Glioma Subtypes
April 15, 2021

A durable clinical benefit was seen from the dual inhibition of the MAPK pathway using BRAF and MEK inhibitors dabrafenib and trametinib, respectively, to treat patients with BRAF V600E mutant low- and high-grade glioma.

Pathogenic Germline Variants Correlate With Worse Survival Outcomes in Neuroblastoma
April 11, 2021

Germline variants in cancer predisposition genes were associated with worse event-free and overall survival in patients with neuroblastoma.

FDA Recommends Early Termination of Phase 2 Trial Investigating ERC1671 to Treat Glioblastoma
April 09, 2021

ERC-USA announced that the FDA recommended the early termination of a phase 2 clinical trial of ERC1671 to treat patients with recurrent or progressive glioblastoma and pursue a randomized confirmatory phase 3 trial.